Cabaletta Bio, Inc. (NASDAQ: CABA) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "inline" rating. They now have a $6.00 price target on the stock, down previously from $15.00.
Cabaletta Bio, Inc. (NASDAQ: CABA) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $6.00 price target on the stock, down previously from $12.00.
Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures [Yahoo! Finance]
Cabaletta Bio, Inc. (NASDAQ: CABA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Cabaletta Bio to Participate in Upcoming Investor Conferences in December [Yahoo! Finance]